Additional file 3 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer

Additional file 3: Supplementary Table S3. List of differentially expressed genes in Indisulam treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05), Supplementary Table S4. List of differentially spliced events in Indisulam treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05), Supplementary Table S5. List of differentially expressed genes in Pladienolide B treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05), Supplementary Table S6. List of differentially spliced events in Pliadenolide B treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05), Supplementary Table S7. List of differentially expressed genes in THZ531 treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05), Supplementary Table S8. List of differentially spliced events in THZ531 treated 22Rv1 cells compared to control (fold change >=2, p-value<=0.05).